Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients

Vaccine

Volumn 25, Issue 10, 2007, Pages 1771-1779

  Yao, Xin ^a   Zheng, Bojian ^b   Zhou, Jie ^b   Xu, Dao Zhen ^c   Zhao, Kai ^d   Sun, Shu Hui ^a   Yuan, Zheng Hong ^a   Wen, Yu Mei ^a  

^a BEIJING HOSPITAL   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Institute of Beijing Increase Biological Products   (China)

Author keywords

Chronic hepatitis B; Cytokines; Dendritic cells; HBsAg anti HBs

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 12;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DENDRITIC CELL; DRUG EFFECT; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL;

EID: 33846650945     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.019     Document Type: Article

References (24)

1. Beasley R.P., Huang L.Y., Lin C.C., and Chen D.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 2 (1981) 1129-1133
2. Szmuness W. Hepatocellular carcinoma and hepatitis B virus-evidence for a causal association. Prog Med Virol 24 (1978) 40-69
3. Sun J., Gao Y., Chen H.S., Wang S.X., Li R.B., Jiang D., et al. Transfusion of multi-factors activated immune cells as a novel treatment for patients with chronic hepatitis B. J Clin Virol 35 (2006) 26-32
4. Jung M.C., Gruner N., Zachoval R., Schraut W., Gerlach T., Diepolder H., et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of vaccine-specific CD4+ T cell proliferative response in chronic hepatitis B carriers. Vaccine 20 (2002) 3598-3612
5. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30 (1999) 531-536
6. Kakimi K., Guidotti L.G., Koezuka Y., and Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192 (2000) 921-930
7. Zheng B.J., Ng M.H., He L.F., Yao X., Chan K.W., Yuen K.Y., et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies recombinant DNA composite in HBsAg transgenic mice. Vaccine 19 (2001) 4219-4225
8. Wen Y.M., Wu X.H., Hu D.C., Zhang Q.P., Guo S.Q., and Hepatitis. B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345 (1995) 1575-1576
9. Wen Y.M., Qu D., Zhou S.H., Zhang Q.P., and Guo S.Q. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Intern Rev Immunol 18 (1999) 251-258
10. Xu D.Z., Huang K.L., Zhao K., Xu L.F., Shi N., Yuan Z.H., et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23 (2005) 2658-2664
11. Zheng B.J., Zhou J., Qu D., Siu K.L., Lam T.W., Lo H.Y., et al. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Virol Hepat 11 (2004) 217-224
12. Seager Danciger J., Lutz M., Hama S., Cruz A., Castrillo C.A., Lazaro J., et al. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods 288 (2004) 123-134
13. Stoop J.N., van der Molen R.G., Baan C.C., Van der Laan L.J., Kuipers E.J., Kusters J.G., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 (2005) 771-778
14. Kimura K., Kakimi K., Wieland S., Guodotti L.G., and Chisari F.V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76 (2002) 10702-10707
15. Lau G.K., Suri D., Liang R., Rigopoulou E.L., Thomas M.G., Mullerova I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122 (2002) 614-624
16. Pancholi P., Lee D.H., Liu Q., Tackney C., Taylor P., Perkus M., et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33 (2001) 448-454
17. Horiike N., Fazle Akbar S.M., Michitaka K., Joukou K., Yamamoto K., Kojima N., et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach fro treating patients with chronic hepatitis B. J Clin Virol 32 (2005) 156-161
18. Wen Y.M., He L.F., Qu D., Ma Z.M., and Yao X. Experimental studies on recombinant hepatitis B immunogenic complex therapeutic vaccine (YIC). Eng Sci China 1 (1999) 113-117 (in Chinese)
19. Wen Y.M., Xiong S.D., and Zhang W. Solid matrix-antibody-antigen complex can clear viremia and antigenemia in persistent duck hepatitis B virus infection. J Gen Virol 75 (1994) 335-339
20. Couillin I., Pol S., Macini M., Driss F., Brechot C., Tiollais P., et al. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Inf Dis 180 (1999) 15-26
21. Pol S., Nalpas B., Driss F., Michel M.-L., Tiollais P., Denis J., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34 (2001) 917-921
22. Liaw Y.F., Leung N., Guan R., Lau G.K.K., Meican I., McCaughan G., et al. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
23. Funk M.L., Rosenberg D.M., and Lok A.S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 9 (2002) 52-61
24. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., et al. CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 (2003) 68-76